Modulating gamma-c-cytokine activity
Embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting yc-cytokine activity involve raising neutralizing antibodies against each individual γc-cytokine family member/′ receptor subunit. However, success has been limited and often multiple γc-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. Such approach allows for flexibility in antagonist design. In several embodiments, peptides exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members.
1. A nucleotide sequence encoding a composite peptide that comprises amino acid sequences of at least two interleukin (IL) protein gamma-c-box D-helix regions, wherein the composite peptide comprises an amino acid sequence having at least 70% sequence identity to the amino acid sequence P-K-E-F-L-E-R-F-V-H-L-V-Q-M-F-I-H-Q-S-L-S (SEQ ID NO: 3), wherein the composite peptide inhibits the activity of IL-15 and IL-21.
2. The nucleotide sequence of claim 1 , wherein the nucleotide sequence is selected from the group consisting of dsDNA, ssDNA, dsRNA, and ssRNA.
3. The nucleotide sequence of claim 1 , wherein the composite peptide consists of the amino acid sequence of SEQ ID NO: 3.
4. A pharmaceutical composition comprising:
a nucleotide sequence encoding a peptide conjugate, or a derivative thereof; and
a pharmaceutically acceptable carrier, diluent, excipient or combination thereof;
wherein the peptide conjugate or the derivative thereof modulates the activity of IL-15 and IL-21;
wherein the peptide conjugate or the derivative thereof comprises an amino acid sequence having at least 70% sequence identity to P-K-E-F-L-E-R-F-V-H-L-V-Q-M-F-I-H-Q-S-L-S (SEQ ID NO: 3).
5. The pharmaceutical composition of claim 4 , wherein the nucleotide sequence further comprises a sequence encoding a signal peptide.
6. The pharmaceutical composition of claim 4 , wherein the nucleotide sequence is selected from the group consisting of dsDNA, ssDNA, dsRNA, and ssRNA.
7. The pharmaceutical composition of claim 4 , wherein the peptide conjugate consists of the amino acid sequence of SEQ ID NO: 3.
8. A method of treating a γc-cytokine-mediated disease, the method comprising administering the pharmaceutical composition of claim 4 to a subject in need of treatment, wherein the γc-cytokine-mediated disease is selected from the group consisting of myasthenia gravis, inflammatory bowel disease, CD4-leukemia, CD8-leukemia, LGL-leukemia, systemic lupus erythematosus, Sjögren's syndrome, Wegener's granulomatosis, Celiac disease, Hashimoto's thyroiditis, rheumatoid arthritis, diabetes mellitus, psoriasis, multiple sclerosis, uvietis, inflammation of the eye, and graft-versus-host disease (GvHD).
9. A method of treating uveitis, arthropathy, dermatitis, exocrinopathy, and myositis, the method comprising administering the pharmaceutical composition of claim 4 to a subject in need of treatment.
10. A method of treating an inflammatory respiratory disease, the method comprising administering the pharmaceutical composition of claim 4 to a subject in need of treatment, wherein the inflammatory respiratory disease is selected from the group consisting of sinusitis, bronchitis, chronic obstructive pulmonary disease (COPD), and lung fibrosis.
11. A method of treating a cosmetic condition, the method comprising administering the pharmaceutical composition of claim 4 to a subject in need of treatment, wherein the cosmetic condition is selected from the group consisting of acne, hair loss, and sunburn.
12. A genetic construct comprising:
a nucleotide sequence encoding a composite peptide; and
at least one regulatory element, wherein the at least one regulatory element is configured to regulate expression of the composite peptide,
wherein the composite peptide, when expressed, can modulate the activity of IL-15 and IL-21;
wherein the composite peptide comprises an amino acid sequence having at least 70% sequence identity to P-K-E-F-L-E-R-F-V-H-L-V-Q-M-F-I-H-Q-S-L-S (SEQ ID NO: 3).
13. The genetic construct of claim 12 , wherein the genetic construct is a DNA.
14. The genetic construct of claim 12 , wherein the genetic construct is an RNA.
15. The genetic construct of claim 12 , wherein the composite peptide consists of the amino acid sequence of SEQ ID NO: 3.
16. The composite peptide encoded by the nucleotide sequence of claim 1 .
17. The composite peptide of claim 16 , wherein the composite peptide is conjugated to one or more additional moieties at the N-terminus, C-terminus, or a side residue of the composite peptide.
18. The composite peptide of claim 17 , wherein the one or more additional moieties is selected from the group consisting of albumin, Keyhold Limpet Hemocyanin (KLH), Fc region of IgG, a biological protein that functions as scaffold, an antibody against a cell-specific antigen, a receptor, a ligand, a metal ion, and Poly Ethylene Glycol (PEG).
19. The composite peptide of claim 17 , wherein the one or more additional moieties comprises Poly Ethylene Glycol (PEG).
20. A method for nail maintenance, the method comprising administering the pharmaceutical composition of claim 4 to a subject in need of nail maintenance.